https://doi.org/10.4081/hmr.v1i2.226

The role of alemtuzumab in the treatment of chronic lymphocytic leukemia (CLL) and the achievement of minimal residual disease negativity in relapsed/refractory CLL

Vol. 1 No. 2: Is Elimination of Minimal Residual Disease Significant for the Outcome of CLL? The Role of Alemtuzumab
Published: May 28, 2009
Abstract Views: 164
PDF: 233
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Peter Hillmen
support@pagepress.org
Chronic lymphocytic leukemia (CLL) is the most common adult hematologic malignancy in the developed world, predominantly affecting the elderly. It is a disease with a very heterogeneous outcome, with some patients surviving for many years without any evidence of progression and others rapidly developing aggressive disease, associated with early bone marrow failure and repeated infections. In recent years, the recognition of novel prognostic markers (e.g. mutational status of the variable region of the immunoglobulin heavy-chain gene [VH],1-4 zeta-associated protein 70 [ZAP70],5-8 and p53 deletion or mutation resistance)9-10 has greatly improved the stratification of patients on the basis of their clinical risk profile, allowing treatment to be tailored accordingly, particularly in patients likely to develop progressive disease. [>Read full article in PDF]

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Hillmen, P. (2009). The role of alemtuzumab in the treatment of chronic lymphocytic leukemia (CLL) and the achievement of minimal residual disease negativity in relapsed/refractory CLL. Hematology Meeting Reports (formerly Haematologica Reports), 1(2). https://doi.org/10.4081/hmr.v1i2.226
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).